Literature DB >> 23269423

Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients.

Tadashi Sofue1, Masashi Inui2, Hideyasu Kiyomoto3, Kumiko Moriwaki4, Taiga Hara4, Kazunori Yamaguchi5, Noriyasu Fukuoka5, Kazuko Banno6, Akira Nishiyama7, Yoshiyuki Kakehi2, Masakazu Kohno4.   

Abstract

BACKGROUND: Excess fluid distribution is a common disorder in peritoneal dialysis (PD) patients. Tacrolimus malabsorption may also occur in PD patients, and may lead to acute allograft rejection after transplantation. The purpose of this study was to evaluate the relationship between tacrolimus pharmacokinetics and excess fluid distribution according to pre-transplant dialysis modality.
METHODS: We retrospectively analyzed 41 adult living-donor kidney transplantations, including nine PD patients and 32 hemodialysis (HD) patients. We examined tacrolimus pharmacokinetics in the peri-operative period and determined the association between the tacrolimus absorption rate and body weight reduction. The absorption efficacy of tacrolimus was evaluated as the dose-normalized tacrolimus absorption rate. Tacrolimus concentrations in PD effluent were measured by high-performance liquid chromatography.
RESULTS: The tacrolimus absorption rate on the day before kidney transplantation tended to be lower in PD patients than in HD patients; however, the rate improved after kidney transplantation and was similar in both groups of patients. The peak tacrolimus concentration time was later in PD patients than in HD patients. The body weight reduction after kidney transplantation was greater in PD patients than in HD patients, and was significantly associated with the change in tacrolimus absorption rate (p=0.04, r=0.32). Only 0.002% of the oral tacrolimus dose was removed by PD itself.
CONCLUSION: Excess fluid distribution in PD patients appears to contribute to tacrolimus malabsorption rather than PD itself. We should consider the risk of tacrolimus malabsorption in patients with possible excess fluid distribution, particularly in PD patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23269423     DOI: 10.1007/s10157-012-0764-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  27 in total

Review 1.  Assessment of dry weight in hemodialysis: an overview.

Authors:  J Q Jaeger; R L Mehta
Journal:  J Am Soc Nephrol       Date:  1999-02       Impact factor: 10.121

2.  Plasma volume, albumin, and fluid status in peritoneal dialysis patients.

Authors:  Biju John; B Kay Tan; Stephen Dainty; Patrik Spanel; David Smith; Simon J Davies
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-10       Impact factor: 8.237

3.  Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians.

Authors:  Iain A M Macphee; Salim Fredericks; Maha Mohamed; Michelle Moreton; Nicholas D Carter; Atholl Johnston; Lawrence Goldberg; David W Holt
Journal:  Transplantation       Date:  2005-02-27       Impact factor: 4.939

4.  The site-specific transport and metabolism of tacrolimus in rat small intestine.

Authors:  Shigeki Tamura; Yuji Tokunaga; Rinta Ibuki; Gordon L Amidon; Hitoshi Sezaki; Shinji Yamashita
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

5.  Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.

Authors:  Norihiko Tsuchiya; Shigeru Satoh; Hitoshi Tada; Zhenhua Li; Chikara Ohyama; Kazunari Sato; Toshio Suzuki; Tomonori Habuchi; Tetsuro Kato
Journal:  Transplantation       Date:  2004-10-27       Impact factor: 4.939

6.  Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry.

Authors:  Yu-Luan Chen; Hideki Hirabayashi; Shahzad Akhtar; Mary Pelzer; Masakazu Kobayashi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-11-28       Impact factor: 3.205

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis.

Authors:  Constantijn J A M Konings; Jeroen P Kooman; Marc Schonck; Ruben Dammers; Emiel Cheriex; Andrea P Palmans Meulemans; Arnold P G Hoeks; Bernardus van Kreel; Ulrich Gladziwa; Frank M van der Sande; Karel M L Leunissen
Journal:  Perit Dial Int       Date:  2002 Jul-Aug       Impact factor: 1.756

9.  Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.

Authors:  K Iwasaki; T Shiraga; K Nagase; Z Tozuka; K Noda; S Sakuma; T Fujitsu; K Shimatani; A Sato; M Fujioka
Journal:  Drug Metab Dispos       Date:  1993 Nov-Dec       Impact factor: 3.922

10.  Pre-existing arteriosclerotic intimal thickening in living-donor kidneys reflects allograft function.

Authors:  Tadashi Sofue; Masashi Inui; Hideyasu Kiyomoto; Masahiro Moritoki; Satoshi Nishioka; Yoko Nishijima; Kumiko Moriwaki; Taiga Hara; Yoshio Kushida; Reiji Haba; Takeshi Yoda; Tomohiro Hirao; Yoshiyuki Kakehi; Akira Nishiyama; Masakazu Kohno
Journal:  Am J Nephrol       Date:  2012-07-13       Impact factor: 3.754

View more
  1 in total

1.  Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients.

Authors:  Tadashi Sofue; Masashi Inui; Taiga Hara; Yoko Nishijima; Kumiko Moriwaki; Yushi Hayashida; Nobufumi Ueda; Akira Nishiyama; Yoshiyuki Kakehi; Masakazu Kohno
Journal:  Drug Des Devel Ther       Date:  2014-02-17       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.